Create your personal agenda –check the favourite icon
Chair’s opening remarks
Keynotes
Navin Joshi, Global Head of Pricing & Access Capabilities, GlaxoSmithKline
Overview of the rare diseases landscape and the challenges facing HTAs
Keynotes
Sheela Upadhyaya, Assoicate Director HST, National Institute for Health and Care Excellence
How to capture and quantify patient value within a commercial strategy
Keynotes
Daniel Jackson, Global Head Of Market Access, Solutions And Strategy, UCB
The Value of a Cure
Keynotes
Jane Erickson, Vice President, Covance Market Access and Phase IV Solutions, Covance Market Access
What is going on in Quebec about Market Access?
Keynotes
- Examining Quebec life sciences strategy: Integration of medicines and technological innovations
- Achieving cost reduction and improving access to medicines
- Re-editing the evaluation process for the introduction of innovative medication and technologies
Luc Boileau, Président-Directeur General, Inesss
The admission of value in the new marketplace
Keynotes
Ryan Saadi, VP, Global Market Access, CSL Behring
Biosimilars Pricing and access expectations in Europe
Keynotes
25 Roundtables (max 15 PAX)
Keynotes
Roundtable 11: The use of registries to assess orphan drugs
Jan Span, Member Of The Cross-Committee Task Force On Registries And Senior Clinical Assessor, Medicines Evaluation Board The Netherlands
Roundtable 12: Making sustainable healthcare work
Michael Schroter, Partner, Viopas Partners
Roundtable 13: “Pricing Strategy – What to Do and When?”
Andreia Ribeiro, Engagement Manager, Lifescience Dynamics Ltd
Roundtable 14: Contract Innovation
Birgit Holz, Global Head Of Contracting Innovation, Sanofi
Roundtable 15: Price Negotiations with Payors in Ireland & the UK
Brenda Dooley, Founder & CEO, Axis Consulting
Roundtable 16: Phase III studies and HTA- or bringing HTA requirement in the development programs
Friedhelm Leverkus, Director Health Technology Assessment And Outcomes Research, Pfizer
Roundtable 17: Working with Estonian Payers
Kart Veliste, Chief Specialist at Department of Medicines and Medical Devices, Haigekassa Estonia
Roundtable 18: Room At The Top? The Case For a Chief Value Officer and The Three Pillars of Responsibility: Value Communication, Value Creation and Value Governance
Roundtable 19: Shaping assets from inception to phase II to maximise pricing & market access potential
Adam Plich, Former Vice President, Head Of Pricing And Market Access Europe, Teva
Roundtable 1: Bridging the gap between clinical development and medical affairs, tailoring clinical trials to meet both MA and HTA requirements
Katerina Anokhina, Director, Medical Affairs, Uk And Ireland, Alexion Pharma UK
Soniya Mokashi, Global Senior Medical Affairs Physician, Norgine
Roundtable 20: Engaging with patients and improving outcomes
Dawn Ireland, President, CDH International
Roundtable 21: Exploring role of evidence in anti-infective value assessments
Keiko Tone, VP Global Market Access, Shionogi Inc
Roundtable 22: GDPR, Big Data, and Re-designing Consent in Health-related Research
Francis Crawley, Executive Director, Strategic Initiative For Developing Capacity In Ethical Review (Sidcer), Good Clinical Practice Alliance (GCPA)
Roundtable 23: The SmPC: friend or foe in access and pricing?
Mauricio Alvarez Reyes, Market Access Expert, Independent
Roundtable 24: Exploring the landscape of drug pricing, spending and affordability in the U.S.
Robert Popovian, Vice President Of Government Relations, Pfizer
Roundtable 2: Examining emerging trends for market access in LMICs, opportunities and challenges
Hector Castro, Senior Technical Director- Pharmaceutical Economics & Financing, Management Science For Health
Roundtable 3: Capability building for RWE
Elena Panitti, Global Rwe Capability Building Lead, Novartis
Melvin Olson, Global Head Rwd Strategy And Innovation, Novartis Pharma
Angelina Irizari Policarpio, Head Of US HEOR Field Team and US Quality, Boehringer Ingelheim
Roundtable 4: Payer engagement in the world of orphan drugs
Fabrizio Zucca, Director Patient Access Dach, Sobi
Roundtable 5: Payer insights and engagement for BeneLux
Roundtable 6: Payer insights and engagement for Russia
Ivan Glushkov, External Affairs Department Director, S.T.A.D.A.
Anastasiya Stepanova, State Authorities Manager, JSC Nizhpharm
Roundtable 7: Role of RWE in oncology
Roundtable 8: Exploring regulatory and market access developments in advanced therapies
Renske Ten Ham, Phd Candidate, Utrecht University
Roundtable 9: Accelerating access to treatments for rare diseases
Chair’s remarks
PRICING & MARKET ACCESS
Chair’s remarks
RARE DISEASES
Chair’s remarks
BIG DATA, DIGITAL HEALTH & ANALYTICS
Alexander Natz, Secretary General, EUCOPE
Chair’s remarks
HTA
Anjan Chatterjee, Global Head Of Real World Evidence, Boehringer Ingelheim Pharma GmbH & Co. KG
Chair’s remarks
EMERGING MARKETS, SOUTH KOREA & JAPAN
Navin Joshi, Global Head of Pricing & Access Capabilities, GlaxoSmithKline
Chair’s remarks
BIOSIMILARS
Steinar Madsen, Medical Director, Norwegian Medicines Agency, Norway
Presentation cancelled
EVIDENCE
Melvin Olson, Global Head Rwd Strategy And Innovation, Novartis Pharma
Developments in indication and combination pricing models
PRICING & MARKET ACCESS
- A look at the reimbursement and pricing environment and challenges for indication-based and combination therapy pricing
- Addressing the information gap: Infrastructure needs
- Where are we? Case studies on indication-based and combo pricing
From drug access to Value Based Healthcare
RARE DISEASES
Lara Pippo, Head Of Market Access, C.S.L. Behring Spa
HTA in the world of digital health.
BIG DATA, DIGITAL HEALTH & ANALYTICS
Defining the value of oncology drugs: the regulatory, HTA and clinicians’ perspective
HTA
Irina Odnoletkova, VP Health Technology Assessment, Apogenix
Emerging trends for market access in LMICs, opportunities and challenges
EMERGING MARKETS, SOUTH KOREA & JAPAN
Hector Castro, Senior Technical Director- Pharmaceutical Economics & Financing, Management Science For Health
The Canadian perspective and experience on Biosimilars
BIOSIMILARS
Elena Lungu, Manager of Policy Development, PMPRB
Biopharmaceutical Acceleration Model for product development and commercialization
EVIDENCE
David Thompson, Senior Vice President, Head of Thought Leadership, Real World And Late Phase Research, Syneos Health
The Transaction Price Opportunity: A Guide to Maximize its Value
PRICING & MARKET ACCESS
Alejandra Garitonandía, X, Vistex
Patient engagement in the world of rare diseases
RARE DISEASES
Ana Palma, Senior Director Global HTA & Patient Access Lead, Sobi
Beyond data - Deriving Actionable Intelligence
BIG DATA, DIGITAL HEALTH & ANALYTICS
Simon Swift, Managing Director, Methods Analytics
Tumour-agnostic agents: are they fit for reimbursement
HTA
Breaking down the ‘Great Wall’: do the evolving market access policy dynamics in China represent the next big opportunity of Pharma?
EMERGING MARKETS, SOUTH KOREA & JAPAN
Amy Wang, Life Sciences Consultant, Navigant
Increasing availability of biosimilars and examining market access policies
BIOSIMILARS
Sue Naeyaert, Vice-President Global Government Affairs, Policy and Pharmacoeconomics Biosimilars, Fresenius Kabi
USA Perspective: FDA’s Framework for Evaluating RWD/ RWE for Use in Regulatory Decisions
EVIDENCE
Nneka Onwudiwe, Founder and Chief Executive Officer, Pharmacoeconomics Consultants of America
The SmPC: friend or foe in access and pricing?
PRICING & MARKET ACCESS
Mauricio Alvarez Reyes, Market Access Expert, Independent
Redesigning pricing for the era of orphan drugs
RARE DISEASES
Herve Lilliu, CEO, inbeeo
The use of Ehealth tools to measure health outcomes for pricing purposes
BIG DATA, DIGITAL HEALTH & ANALYTICS
Geert Pelsmaeker, General Manager, Leaphy
European HTA - chances and risks. A German payer's view
HTA
Michael Ermisch, Specialist, Department Of Pharmaceuticals, G.K.V. Spitzenverband
How to expand access to wider populations in Low & Middle Income countries: the business impact of innovative thinking
EMERGING MARKETS, SOUTH KOREA & JAPAN
Chair’s remarks
EVIDENCE
Angelina Irizari Policarpio, Head Of US HEOR Field Team and US Quality, Boehringer Ingelheim
Chair’s remarks
PRICING & MARKET ACCESS
Diane Munch, Head Of Global Pricing, Patient And Health Impact, Pfizer
Chair’s remarks
RARE DISEASES
Axel Boehnke, Director Market Access (Global Responsibility), MorphoSys AG
Chair’s remarks
BIG DATA, DIGITAL HEALTH & ANALYTICS
Francis Crawley, Executive Director, Strategic Initiative For Developing Capacity In Ethical Review (Sidcer), Good Clinical Practice Alliance (GCPA)
Chair’s remarks
EMERGING MARKETS, SOUTH KOREA & JAPAN
Birgit Holz, Global Head Of Contracting Innovation, Sanofi
Chair’s remarks
BIOSIMILARS
Steinar Madsen, Medical Director, Norwegian Medicines Agency, Norway
RWE – disrupter or quiet evolution?
EVIDENCE
Sandy Leonard, Vice President Of Medical Evidence And Observational Research, AstraZeneca
Market access requirements in Germany
PRICING & MARKET ACCESS
Marco Penske, Head Of Market Access And Health Care Affairs, Boehringer Ingelheim Biopharmaceuticals Gmbh
Using payer data to support rare disease treatments in Germany
RARE DISEASES
- Reliability
- Analyses
- Outcome
Axel Boehnke, Director Market Access (Global Responsibility), MorphoSys AG
Benefit assessment of orphan drugs in Germany
BIG DATA, DIGITAL HEALTH & ANALYTICS
Friedhelm Leverkus, Director Health Technology Assessment And Outcomes Research, Pfizer
Why investors care about value and affordability
VALUE
Michael Schroter, Partner, Viopas Partners
The Sanofi Espoir Foundation- Providing new payment access systems to emerging markets
EMERGING MARKETS, SOUTH KOREA & JAPAN
Valerie Faillat, Head Of Sanofi Espoir Foundation, Sanofi
How to fill in the gap: improving patient access to value-added medicines
BIOSIMILARS
Catarina Lopes Pereira, Market Access Manager, Medicines for Europe
Spending trends for cancer. What does the evidence say?
EVIDENCE
Early Integrated Scientific Advice: A Key to Optimal PRMA?
PRICING & MARKET ACCESS
4D Insights - powering access
BIG DATA, DIGITAL HEALTH & ANALYTICS
- Aligning Payers, Policy Markers, Prescribers and Patient Insight using the power of Big Data
- Real-time Insights giving competitive advantage
- Measuring impact in real-time from within the health system
David Williams, Chief Medical Officer, Visformatics
Creating Value with Outcome Based Contracts: a case from the industry
VALUE
Sania Chouman, Global Market Access Lead, Takeda
Insights into the new HTA roll out in Japan
EMERGING MARKETS, SOUTH KOREA & JAPAN
Taro Fujimoto, Policy & External Affairs Manager, Bayer Pharmaceuticals
Rewarding Innovation in Drug Development
RARE DISEASES
Emily Saadi, Senior Undergraduate, Health Care Policy & Management, Georgetown University
Delivering affordable and sustainable medicines to patients across Europe through Biosimilars
BIOSIMILARS
Steinar Madsen, Medical Director, Norwegian Medicines Agency, Norway
What patients expect from clinical research and researchers - and how patient advocacy can help deliver it
EVIDENCE
Richard Stephens, Chair Of Consumer Liaison Group, National Cancer Research Institute (NCRI)
The pharmaceutical market of the Russian Federation: trends and prospects
PRICING & MARKET ACCESS
Anastasiya Stepanova, State Authorities Manager, JSC Nizhpharm
Ivan Glushkov, External Affairs Department Director, S.T.A.D.A.
GDPR, Big Data, and Re-designing Consent in Health-related Research
BIG DATA, DIGITAL HEALTH & ANALYTICS
Francis Crawley, Executive Director, Strategic Initiative For Developing Capacity In Ethical Review (Sidcer), Good Clinical Practice Alliance (GCPA)
Measuring the value of improved workflow efficiency and safety of drug administration with prefilled syringes
VALUE
Marie-Liesse Le Corfec, Global Portfolio Marketing Head, PS, B.D. Pharmaceuticals Systems
Reimbursement and risk-sharing in South Korea
EMERGING MARKETS, SOUTH KOREA & JAPAN
Jeonghoon Ahn, Director, National Evidence-based Healthcare Collaborating Agency
Chair’s remarks
EVIDENCE
Deven Chauhan, Senior Director, Value Evidence Leader, GlaxoSmithKline
Chair’s remarks
PRICING & MARKET ACCESS
Cristina Martin-Rinconada, Head of Value & Access for International Partners Markets (MENA & CEER Regions), Biogen
Chair’s remarks
RARE DISEASES
Chair’s remarks
BIG DATA, DIGITAL HEALTH & ANALYTICS
Waldemar Ockert, Director, RWI Business Market Analytics, Astellas
Chair’s remarks
EMERGING MARKETS, SOUTH KOREA & JAPAN
Camille Harfouche, Regional Office Lead, Algorithm
Chair’s remarks
BIOSIMILARS
Steinar Madsen, Medical Director, Norwegian Medicines Agency, Norway
Chair’s remarks
REIMBURSEMENT
Igor Rudychev, Senior Director, Business Insights, AstraZeneca
Use of value frameworks within oncology in Europe
EVIDENCE
- Innovation and launches in oncology are moving at a rapid pace, potentially resulting in a delay in formal reimbursement appraisal and guidance
- A number of value frameworks have been developed with the intent of providing rapid advice to oncologists on the clinical benefit of these new drugs
- These value frameworks have many advantages, including clarity and brevity, but they do not replace the full value assessment of a formal HTA
Gwilym Thompson, Director Worldwide Heor, BMS
Integrating care to secure early access and effective pricing
PRICING & MARKET ACCESS
Andrea Mantovani, Market Access Expert, Independent
Utilising disease registries for orphan drug launch
RARE DISEASES
- Utilising disease registries is vital in rare diseases and a multicountry, multi-stakeholder approach will be discussed
- In Europe, linkage is needed as well between registries and EU Reference networks and this can prove to be an invaluable relation ship
- Technological challenges are a problem and potential approaches will be explored
Peter Rutherford, Global Medical Lead Of Orphan Renal Diseases, Vifor Pharma Group
Digital Therapeutics: The promise and the evidence
BIG DATA, DIGITAL HEALTH & ANALYTICS
Oliver Gassner, Head Digital Health Intelligence | Emea, Bayer
Working with stakeholders to facilitate the entry of CAR-T in Europe
EMERGING MARKETS, SOUTH KOREA & JAPAN
Neil Mulcock, Vice President Government Affairs and Policy, Gilead Sciences
The Belgian perspective and recent experiences in the regulatory biosimilar landscape
BIOSIMILARS
Roadmap to Reimbursement: A Review of Successes and Stumbles
REIMBURSEMENT
Using RWE across the life cycle
EVIDENCE
Anne Marciniak, Head of Market Access, Europe, Aimmune
Review of International Reference Pricing
PRICING & MARKET ACCESS
Marketing authorisation application for ultra orphan drugs
RARE DISEASES
Jan Span, Member Of The Cross-Committee Task Force On Registries And Senior Clinical Assessor, Medicines Evaluation Board The Netherlands
Access environment and challenges in the Middle East and North Africa
EMERGING MARKETS, SOUTH KOREA & JAPAN
Camille Harfouche, Regional Office Lead, Algorithm
Realising the insurance business model to establish effective partnership working
REIMBURSEMENT
Charles De Cidrac, Director Of Health Insurance, AXA
Access to Medicines & Access to Health-related Research: Digital Health Literacy and a European Public Health Library
BIG DATA, DIGITAL HEALTH & ANALYTICS
Francis Crawley, Executive Director, Strategic Initiative For Developing Capacity In Ethical Review (Sidcer), Good Clinical Practice Alliance (GCPA)
Discussion: Summary of thoughts & Q/A
BIOSIMILARS
Steinar Madsen, Medical Director, Norwegian Medicines Agency, Norway
Bart Vermeulen, Deputy Director Healthcare At Office Of The Minister Of Social Affairs And Public Health, Belgian Federal Government
Elena Lungu, Manager of Policy Development, PMPRB
Catarina Lopes Pereira, Market Access Manager, Medicines for Europe
Sue Naeyaert, Vice-President Global Government Affairs, Policy and Pharmacoeconomics Biosimilars, Fresenius Kabi
Evidentry standards for RWE in a changing world
EVIDENCE
Chris L Pashos, Vice President Of Global Evidence Strategy, AbbVie
Insights for NICE: The evolving landscape for market access
PRICING & MARKET ACCESS
Carla Deakin, Programme Director – Commercial & Managed Access, NICE
Innovative Value based contracting for gene therapy
RARE DISEASES
Emerging Market and Vaccines
EMERGING MARKETS, SOUTH KOREA & JAPAN
Alen Marijam, Heor Senior Manager, Em, GlaxoSmithKline
Reimbursement within the world of Oncology
REIMBURSEMENT
- Oncology Environment and Patient Access to the Oncology Therapies
- Patient Access & Support Programs in Oncology
- Reimbursement issues and impact of the reimbursement delays in Oncology
Igor Rudychev, Senior Director, Business Insights, AstraZeneca
Create your personal agenda –check the favourite icon
Chair’s opening remarks
Keynotes
Germany and the EU: current developments
Keynotes
Thomas Mueller, Head Of Directorate General 1 "Drugs, Medical Devices, Biotechnology", Federal Ministry of Health Germany
Innovative Solutions for Fast-Track Approvals
Keynotes
Achieving greater collaboration amongst payers, HTAs, pharma and patients to improve access and pricing
Keynotes
- Overview of key European and global initiatives and next steps
- Looking at the role of technological innovation in access, pricing and evidence
- Working with payers, patients and pharma to generate value
Gustavo Saraiva Dos Anjos, Head of Market Access, Respiratory Pipeline, GlaxoSmithKline
Andreia Ribeiro, Engagement Manager, Lifescience Dynamics Ltd
Jaume Vidal, Policy Advisor-Europe, Health Action International
Saira Jan, Director Of Pharmacy Strategy And Clinical Integration, Blue Cross Blue Shield of New Jersey
Thomas Mueller, Head Of Directorate General 1 "Drugs, Medical Devices, Biotechnology", Federal Ministry of Health Germany
Roundtables
Keynotes
Nicki Catterick-Kang, Head of Pricing UK and Ireland, Merck Group
Adam Plich, Former Vice President, Head Of Pricing And Market Access Europe, Teva
Mark Macgregor, Co-Vice Chair, Scottish Medicines Consortium, Nhs Scotland
Anindita Sinha, Director, Global Market Access, Pfizer
Katja Rudell, Honorary Research Fellow, Queen Mary University of London
Mario Ouwens, Statistical Science Director, Astra Zeneca
Bart Van Den Daele, Head of External Affairs – Director Market Access, Gilead Sciences Belgium Bvba
Bertrand Tardivel, General Manager, Frehel GmbH
Josie Godfrey, Independent, Duchenne
Ed Pezalla, Former Vice President, National Medical Director For Pharmaceutical Policy And Strategy, Aetna
Matt Slabbert, Head Of Market Access, Advocacy And Policy, Anz, Bayer Pharmaceuticals
Tal Morginstin, Director, Nlhs (National List Of Health Services) Assessment Division, Ministry of Health
Melissa Paige, Uva Cancer Center, Oncology Patient Access Principal Coordinator, Patient Advocate, U.V.A. Health System
Anne Marciniak, Head of Market Access, Europe, Aimmune
Anna Bucsics, Project Advisor, Mechanism of Coordinated Access to orphan medicinal products (MoCA)
Hassan Bruneo, Associate Director, Alnylam Switzerland Gmbh
Jenny Ebert, National Account Director, Genzyme Sanofi Corp
Richard Stephens, Chair Of Consumer Liaison Group, National Cancer Research Institute (NCRI)
Simon Shohet, Senior Director, Global Market Access And Pricing, Ipsen
Chair’s remarks
EVIDENCE
Gundula Schneidewind, Head Ethics & Compliance, Europe & Canada, Takeda
Chair’s remarks
PRICING AND MARKET ACCESS
Elizabeth Mckenna, Head Of Market Access Uk And Ireland, Vertex Pharmaceuticals
Chair’s remarks
RARE DISEASES
Josie Godfrey, Independent, Duchenne
Chair’s remarks
AFFORDABILITY
Chair’s remarks
ADVANCED THERAPIES
Chair’s remarks
MANAGED ENTRY AGREEMENTS
Giuseppe Rosano, Member Of The Cardiovascular Working Party, European Medicines Agency
Federated & Harmonised Real World Research in the EU 2020+: A Convergence of Intent, Collaboration & Technology?
EVIDENCE
- The next decade of RWD/RWE-based research in Europe – the federated model and edge analytics
- Data harmonisation – an international initiative and the Rosetta Stone of RWD?
- What have we learned from IMI EMIF, from its original inception, project experience, and sustainability scale up
- The premise for EHDN, aims and likely impact
- Meeting the needs of multiple stakeholders
Learnings from the Netherlands in the world of pricing and market access
PRICING AND MARKET ACCESS
Jolanda Koenders, Head Of Pricing And Market Access Pharma, Novartis
Value based medicine: whose values?
RARE DISEASES
Mark Macgregor, Co-Vice Chair, Scottish Medicines Consortium, Nhs Scotland
Pharmaceutical Affordability
AFFORDABILITY
- Ability to Pay versus Willingness to Pay
- Considerations for Product-specific and Patient-specific affordability programs
- Partnering with payers/policy makers
John Alter, Vice President Pricing And Market Access, Pfizer
Developing advanced therapies for rare disease: is this sustainable?
ADVANCED THERAPIES
Diego Ardigo, Research And Development Rare Diseases Unit Head, Chiesi Farmaceutici SpA
Latest developments in managed entry agreements for Europe
MANAGED ENTRY AGREEMENTS
Birgit Holz, Global Head Of Contracting Innovation, Sanofi
EUnetHTA and Joint Assessments: Focus on the BeNeLuxA Collaboration
PRICING AND MARKET ACCESS
Rosemary Jose, Director, Strategic Market Access, Pharmerit International
Update on MoCA
RARE DISEASES
Anna Bucsics, Project Advisor, Mechanism of Coordinated Access to orphan medicinal products (MoCA)
Solving the affordability problem – partnering for improved value description is the following
AFFORDABILITY
Health Economic Modelling in Gene Therapies
ADVANCED THERAPIES
Gene therapies raise new challenges when it comes to developing models for use in health technology assessment (HTA), burden of illness and value demonstration. Tried-and-true methods pose special issues, as applied to genetic interventions. This session is a discussion of potential approaches to modeling for gene therapies, and the advantages and disadvantages of various modeling approaches as applied to these interventions.
Ion Agirrezabal, Senior Consultant, Covance Market Access and Phase IV Solutions, Covance Market Access
The role of evidence in anti-infective value assessments
EVIDENCE
Keiko Tone, VP Global Market Access, Shionogi Inc
Implementation of managed entry agreements over the last decade in Australia
MANAGED ENTRY AGREEMENTS
Matt Slabbert, Head Of Market Access, Advocacy And Policy, Anz, Bayer Pharmaceuticals
Understanding the US healthcare model: examining oncology treatments
PRICING AND MARKET ACCESS
Ed Pezalla, Former Vice President, National Medical Director For Pharmaceutical Policy And Strategy, Aetna
Market access considerations for rare disease treatments
RARE DISEASES
Simon Shohet, Senior Director, Global Market Access And Pricing, Ipsen
Achieving affordability in South America
AFFORDABILITY
Andres Pichon Riviere, Executive Director And Director Of Health Technology Assessment And Economic Evaluations, I.E.C.S.
Access considerations in the world advanced therapies
ADVANCED THERAPIES
- CAR T-Cell Therapy, a new therapeutic approach: Between euphoria and scepticism
- Drug or therapeutic method: first experiences in the German health care system
- Most expensive cancer treatment ever: New approaches for affordability and sustainability
Bertrand Tardivel, General Manager, Frehel GmbH
Chair’s remarks
EVIDENCE
Anne Marciniak, Head of Market Access, Europe, Aimmune
Chair’s remarks
PRICING AND MARKET ACCESS
David Watson, Director Pricing And Reimbursement, ABPI
Chair’s remarks
RARE DISEASES
Inge Bliestle, Chief Operating Officer, TolerogenixX
Chair’s remarks
CONTRACTING AND PRICE TENDERING
Marcela Junqueira, Head Of Strategic Affairs And Health Economics, Janssen Pharmaceutical
Chair’s remarks
ADVANCED THERAPIES
Chair's remarks
PATIENT AND PAYER ENGAGEMENT
Ad Schuurman, Senior Advisor International Affairs, National Health Care Institute (ZIN), the Netherlands
Precision medicine in oncology: challenges and possible solutions from a payer’s perspective
EVIDENCE
- What are the key challenges we face in commissioning tests and treatments in this fast-paced and innovative field?
- How can we ensure our patients have access to tests and treatments that are safe and effective despite limited evidence?
- What solutions could be considered to manage costs to payers (and our customers) and safeguard precision medicine as a sustainable option in the future?
Lucy Hoppe, Clinical Effectiveness Manager (Evidence Synthesis) In The Clinical Effectiveness Team, Bupa
Access in the new NHS landscape
PRICING AND MARKET ACCESS
Diar Fattah, Associate Director Of Medicines Optimisation, N.H.S._Dartford Gravesham and Swanley C.C.G.
Launching rare disease products to a world market
RARE DISEASES
Launch success and challenges in establishing the optimal price and contracting strategy
CONTRACTING AND PRICE TENDERING
Steve Sandor, Vice President, Market Access and Trade, Paratek Pharmaceuticals , Inc.
Developments in CAR-T for Russia
ADVANCED THERAPIES
Daria Tolkacheva, Head Of Health Economics, JSC BIOCAD
Engaging with patients and improving outcomes
PATIENT AND PAYER ENGAGEMENT
Dawn Ireland, President, CDH International
Ensuring evidence generation plans support value: Influencing early stage development
EVIDENCE
Deven Chauhan, Senior Director, Value Evidence Leader, GlaxoSmithKline
Quantifying the ‘patient voice’: the importance of tolerability and quality-of-survival in HTA decisions
PRICING AND MARKET ACCESS
- HTA and payer-relevant quantitative concepts to characterize AE profiles and tolerability will be reviewed
- HTA acceptance of these quant. approaches will be illustrated and appraised
- Examples and (potential future) approaches, for HTA and Access success will be discussed
Reg Waldeck, Market Access Strategy Leader, Bayer Corp
Clinical uncertainties management: can PBRSA fill the gap and optimize orphans’ market access?
RARE DISEASES
Entela Xoxi, Former Aifa, Universita Cattolica Del Sacro Cuore
Risks in CAR-T commercialisation - understanding barriers to entry
ADVANCED THERAPIES
Bridging payer and regulatory rules: How far are we?
PATIENT AND PAYER ENGAGEMENT
Ad Schuurman, Senior Advisor International Affairs, National Health Care Institute (ZIN), the Netherlands
Contracting and price tendering for cancer treatments
CONTRACTING AND PRICE TENDERING
Marcela Junqueira, Head Of Strategic Affairs And Health Economics, Janssen Pharmaceutical
Industry and payer collaboration: A Myriad Genetics Case Study
EVIDENCE
Laura O'Hanlon, Associate Director, International Market Access/Reimbursement, Myriad genetics
Pricing and reimbursement in Russia
PRICING AND MARKET ACCESS
Pursuing a successful market access strategy in the world of orphan drugs
RARE DISEASES
Using evidence to support pricing for gene therapies
ADVANCED THERAPIES
Omar Dabbous, VP, Health Economics And Outcomes Research, AveXis Inc
Evolving the payer partnership to foster greater innovation
PATIENT AND PAYER ENGAGEMENT
Dan Pettitt, VP Immunology Market Access and Policy Global Commercial Strategy Organization, Janssen Pharmaceuticals
Chair’s remarks
PRICING AND MARKET ACCESS
Anna Bucsics, Project Advisor, Mechanism of Coordinated Access to orphan medicinal products (MoCA)
Chair’s remarks
RARE DISEASES
Kate Adcock, Director Of Research And Innovation, The Muscular Dystrophy U.K.
Chair’s remarks
MEDICAL AND GOVERNMENTAL AFFAIRS
Robert Popovian, Vice President Of Government Relations, Pfizer
Chair’s remarks
ADVANCED THERAPIES
Alexander Natz, Secretary General, EUCOPE
Chair’s remarks
PATIENT AND PAYER ENGAGEMENT
Anindita Sinha, Director, Global Market Access, Pfizer
Pay for performance: discussing the first large scale study into efficacy of the model
EVIDENCE
Developments in pricing and patient access for speciality treatments
PRICING AND MARKET ACCESS
Diann Potestio, VP Market Access, Ascendis Pharma A/S
Accelerating access to treatments for rare diseases
RARE DISEASES
Kate Adcock, Director Of Research And Innovation, The Muscular Dystrophy U.K.
Accounting profitability and the political process: the case of R&D accounting in the pharmaceutical industry
MEDICAL AND GOVERNMENTAL AFFAIRS
Examining the regulatory landscape for CAR-T
ADVANCED THERAPIES
- CAR T-Cell Therapy, a new therapeutic approach: Between euphoria and scepticism
- Drug or therapeutic method: first experiences in the German health care system
- Most expensive cancer treatment ever: New approaches for affordability and sustainability
Detlev Parow, Head Pharmaceutical Department, D.A.K.
Best practices in the role of patient advocates in EUnetHTA Joint Assessments
PATIENT AND PAYER ENGAGEMENT
Rudy Dupree, Senior Project Manager, Zorginstituut
The SIDE-L framework: when is an observational trial good enough to be used for labeling purposes
EVIDENCE
Mario Ouwens, Statistical Science Director, Astra Zeneca
Ensuring a successful entry into the Danish hospital sector
PRICING AND MARKET ACCESS
Sune Lindgaard, Chief Of Business Intelligence, Amgros, Denmark
Medical drug management a US payer perspective
MEDICAL AND GOVERNMENTAL AFFAIRS
Saira Jan, Director Of Pharmacy Strategy And Clinical Integration, Blue Cross Blue Shield of New Jersey
From AD to oncology – the role of the patient in reimbursement
PATIENT AND PAYER ENGAGEMENT
Anindita Sinha, Director, Global Market Access, Pfizer
Solving the evidence crisis: patient driven collaborations
RARE DISEASES
Josie Godfrey, Independent, Duchenne
Market access for ATMPs in Germany
ADVANCED THERAPIES
Alexander Natz, Secretary General, EUCOPE
The role of RWE in HTAs and regulatory affairs in Germany
EVIDENCE
Jorg Tomeczkowski, Head Of Market Access, Janssen Cilag Germany
HTA in Switzerland
PRICING AND MARKET ACCESS
- Legal Context of HTA in Switzerland
- HTA Processes
- Implementation of HTA
Landscape of Drug Pricing, Spending and Affordability In The U.S.
MEDICAL AND GOVERNMENTAL AFFAIRS
Robert Popovian, Vice President Of Government Relations, Pfizer
Speaking the Language of Patient Engagement
PATIENT AND PAYER ENGAGEMENT
Melissa Paige, Uva Cancer Center, Oncology Patient Access Principal Coordinator, Patient Advocate, U.V.A. Health System
Chair's closing remarks
EVIDENCE
Chair's closing remarks
PRICING AND MARKET ACCESS
Anna Bucsics, Project Advisor, Mechanism of Coordinated Access to orphan medicinal products (MoCA)
Chair's closing remarks
RARE DISEASES
Kate Adcock, Director Of Research And Innovation, The Muscular Dystrophy U.K.
Chair's closing remarks
ADVANCED THERAPIES
Alexander Natz, Secretary General, EUCOPE
Chair's closing remarks
PATIENT AND PAYER ENGAGEMENT
Anindita Sinha, Director, Global Market Access, Pfizer
Chair's closing remarks
MEDICAL AND GOVERNMENTAL AFFAIRS
Robert Popovian, Vice President Of Government Relations, Pfizer
last published: 18/Mar/19 14:45 GMT
Password must meet the following requirements:
- At least one letter
- At least one capital letter
- At least one number
- Be at least 6 characters
Abbes Cadi-Tazi, Consultant,
Lifescience Dynamics Ltd
Abbes is a Consultant based in our UK office and joined the firm in 2015. He is involved in market research, competitive intelligence and market access consulting projects across various therapeutic areas.
Prior to joining Lifescience Dynamics, Abbes worked in several advisory firms dedicated to...
Pedro Borga, Consultant,
Lifescience Dynamics Ltd
Pedro works as a Consultant at the London headquarters of Lifescience Dynamics. Prior to joining Lifescience Dynamics, he worked as a consulting Business Analyst at IMS Health (now IQVIA).Pedro has obtained a bench-to-bedside view of pharmaceuticals through diverse roles including translational...
Don Creighton, Managing Director,
Huron
Don Creighton has more than 20 of years of experience in industry, consulting and scientific research with expert knowledge of payer systems and pricing & market access strategy.Don has worked across a broad array of therapy areas and geographies with projects spanning the development continuum ...
Francis Arickx, Head Of The Directorate Reimbursement Of Medicines And Pharmaceutical Policy,
National Institute for Health and Disability Insurance RIZIV-INAMI
Francis Arickx is the secretary for the Commission for Reimbursement of Medicines at the National Institute for Health and Disability Insurance (NIHDI RIZIV/INAMI) in Belgium. In the directorate Pharmaceutical Policy within the Health Department, he manages the teams responsible for administrative ...
Diane Kleinermans, Advisor To The Ministry Of Health And Social Affairs,
Belgian Federal Government
Diane Kleinermans works as advisor to the Minister of Public Health and Social Affairs since 2015. She is mainly in charge of dossiers related to clinical trials but also of the BeNeLuxA cooperation’s initiative. Diane has a medical background and a broad experience in various fields. She started...
Vitaly Omelyanovskiy, General Director, Center Of Healthcare Quality Assessment And Control,
Federal State Budgetary Institution, the Center for Healthcare Quality Assessment and Control of the Ministry of Health of the Russian Federation
In 1987 he graduated from Pirogov Russian National Research Medical University with a specialization in “General Medicine”. In 1998 he graduated from the Russian Presidential Academy of National Economy and Public Administration with a specialization in “State and Municipal Management”. In 1991 he...
Patrick Mollon, Former Director Gheore,
Shire
Patrick Mollon, MD, ESSEC MBA, MSc acquired his medical qualification in Lyon’sSchool of Medicine, France where he also gained a Masters Degree in Medical andBiological Sciences, including Pharmacology, Psychology and Medical Statistics. Priorto this, he received an MBA from the Superior School of...
Nicholas Bungay, Director of Campaigns, Care and,
Muscular Dystrophy Campaign
Having worked in parliament, Nic joined Muscular Dystrophy UK in May 2007 as Policy and Campaigns Manager. In 2011, he was appointed Director of what is now the Care, Campaigns and Information team.Under Nic’s leadership, his team works closely with families living with muscle-wasting conditions to ...
Patrick Hopkinson, Executive Director, Wwheor Markets,
Bristol-Myers Squibb
Patrick is Executive Director World Wide Health Economics and Outcomes Research (WWHEOR) Markets at Bristol Myers Squibb. He leads the team responsible for supporting country HTA submissions and access. He is responsible for all countries outside of the US. Patrick also leads WWHEOR HTA Policy...
Kevin Mayo, Head, Global Market Access - New Products,
Shire Pharmaceuticals
Dr. Kevin Walker Mayo is Global Head, Market Access New Products for PTC Therapeutics where he is supporting their gene therapy, alternative splicing, nucleotide repeat, protein modification, transcript regulators and nonsense readthrough scientific platforms for discovering rare disease...
Wills Hughes-Wilson, Head Of Patient Access And Commercial Planning,
Mereo BioPharma
Wills Hughes-Wilson is Head of Patient Access & Commercial Planning at Mereo Biopharma and a member of the company’s executive leadership team. She joined Mereo in February 2018 with responsibility for leading and optimising the company’s patient access and commercialisation strategies. Prior...
Marco Rauland, Vice President, Map GmAndE And Training Academy, Global Market Access And Pricing, Biopharma| Global Operations,
Merck Group
Marco Rauland has more than 20 years of drug development, marketing, market research and pricing consulting experience in the pharmaceutical industry. Prior to joining Merck Marco was Vice President Europe of GfK's Market Access practice. Before that Marco was the global head of the...
Nadeem Ashraf, Medical Advisor - Diabetes,
N/A
Nadeem Ashraf is a medical advisor- diabetes for a pharmaceutical company in the UK. Nadeem is registered with General Medical Council- UK as a medical doctor and holds 15 years of cross functional experience across the Pharmaceutical industry ranging from brand management & sales leadership...
Basmah Khogeer, Engagement Manager, Global Pricing, Market Access and Analytics,
Precision Xtract
Basmah Khogeer is an Engagement Manager in the Global Pricing, Market Access and Analytics line at Precision Xtract. Basmah brings 3 years consulting experience focusing on pricing and market access in a variety of therapeutic areas including oncology, haematology, rheumatoid arthritis and rare/...
Nusayba Anjarwalla, Engagement Manager, Global Pricing, Market Access and Analytics line,
Precision Xtract
Nusayba Anjarwalla is an Engagement Manager in the Global Pricing, Market Access and Analytics line of Precision Xtract. Nusayba has 3.5 years consulting experience in a variety of therapeutic areas, including oncology, cardio-vascular disease, ophtmamology and obesity. Her current projects include ...
Giovanny Leon, Pricing And Market Access Director For Latin America And Canada,
Novartis Ag
Giovanny current role is Pricing & Access Regional Director for Novartis Latin-America & Canada. Nevertheless his interest and area of expertise involves access initiatives for Emerging Markets, developing tools and methodologies to measure affordability and solutions to overcome the out...
Rafaat Rahmani, President,
Lifescience Dynamics Ltd
Rafaat founded Lifescience Dynamics in the summer of 2004. Now 14 years on, Lifescience Dynamics is privileged to boast an extraordinary worldwide customer base with teams across the globe supporting firms of all sizes, from top 20 pharmaceutical companies through to smaller niche pharma and...
Christina Vandoros, Director, Macroeconomics & Health Policy - EMEA,
Janssen
Christina Vandorou is currently the Director of Macroeconomics and Health Policy for Europe, Middle East and Africa at Janssen.In the past she has worked in a variety of Local, European and Global positions in the areas of Health Economics, Pricing and Reimbursement, and Government Affairs and...
Matthew Bending, Senior Principal and Executive Director of HTA Strategy, Market Access Consulting,
Evidera
Matthew Bending, PhD, is the Senior Principal and Executive Director of HTA Strategy, Market Access Consulting at Evidera. Dr. Bending is a Health Economist with a PhD in Health Sciences studying the use of Health Technology Assessment (HTA) in reimbursement decision-making with over 14 years...
Meike Wenzel, Partner,
Executive Insight Healthcare Consultants
Meike has deep experience in designing customer centric strategies, especially also in rare diseases. Her focus is on developing and implementing value-based and beyond-the-pill approaches for diverse customer and stakeholder groups including policy makers, payers, professionals, and patients.
Michael Blackney, Director,
Covance
Director – Mike Blackney, PhD. Mike heads up the Payer Insights and Access group at Covance Market Access which focuses on delivering strategic global payer research-based projects for pharmaceutical and medical device manufacturers. Prior to joining Covance in 2010, he worked as a Research...
Diane Kleinermans, Advisor To The Ministry Of Health And Social Affairs,
Belgian Federal Government
Diane Kleinermans works as advisor to the Minister of Public Health and Social Affairs since 2015. She is mainly in charge of dossiers related to clinical trials but also of the BeNeLuxA cooperation’s initiative. Diane has a medical background and a broad experience in various fields. She started...
Alison Kneen, Vice President, Global Access Advisory,
DRG Abacus
Alison Kneen is a Practice Lead at DRG Abacus. She has a passion for market access and public affairs and is seen as a global expert in all aspects of market access and reimbursement strategies. She brings extensive international experience built over 34 years in the pharmaceutical industry, with...
Alan Crowther, General Manager, Global Pricing & Access Solutions,
EVERSANA
Alan has spent close to 20 years doing commercial work for the life sciences industry. His experience includes creating innovative solutions for global pricing and access, including work on price optimization, global data collection and analysis, and the use of advanced algorithms to support...
Kevin Mayo, Head, Global Market Access - New Products,
Shire Pharmaceuticals
Dr. Kevin Walker Mayo is Global Head, Market Access New Products for PTC Therapeutics where he is supporting their gene therapy, alternative splicing, nucleotide repeat, protein modification, transcript regulators and nonsense readthrough scientific platforms for discovering rare disease...
Martina Flammer, Senior Vice President, Head of Corporate Customer Value,
Boehringer Ingelheim International Gmbh
Martina operates at the forefront of functional developments in Market Access, Pricing & HEOR, Epidemiology and Real World Evidence (RWE) to advance state-of-the-art standards and ensure they are consistently applied and met throughout the organization from drug development, via product...
Oliver Leatham, Global Head of Value & Access,
Certara
Oliver has worked for 18 years in market access for both big and small pharma, as well as in European and Global Market Access Consultancy. Oliver is currently Vice President and Global Head of Value & Access for Certara. Oliver’s expertise is in Fast-Track medicine approvals and...
Martina Flammer, Senior Vice President, Head of Corporate Customer Value,
Boehringer Ingelheim International Gmbh
Martina operates at the forefront of functional developments in Market Access, Pricing & HEOR, Epidemiology and Real World Evidence (RWE) to advance state-of-the-art standards and ensure they are consistently applied and met throughout the organization from drug development, via product...
Tamir Singer, Head Of Commercial Development, Specialised Commissioning,
NHS England
Tamir is the Head of Commercial Development in Specialised Commissioning, NHS England and responsible for the negotiations and transactions with Pharmaceutical companies on new high-cost and tariff-excluded drugs for NHS England, such as Managed Access Agreements, promoting innovation and...
Nigel Hughes, Scientific Director,
Janssen
Scientific Director, RMEDS Quantitative Sciences, Janssen Pharm R&D. A former UK NHS healthcare & voluntary sector professional working in the pharmaceutical and diagnostics industry with a 360° experience in the blood borne virus market based on a professional heritage in the viral...
Adam Kundzewicz, Senior Global Payer Strategy Manager, Head Of Pricing,
Boehringer Ingelheim Pharma GmbH & Co. KG
Adam is a Senior Global Payer Strategy Manager working in oncology pipeline at Boehringer Ingelheim. He is managing global pricing and market access strategies for the oncology portfolio and driving the development of innovative market access approaches and payment schemes. Since September 2015 he...
Ajan Reginald, Chief Executive Officer,
Celixir
Ajan Reginald is a co-founder and the Chief Executive Officer of Celixir, which he originally founded under the name Cell Therapy Ltd in 2009 with Nobel Laureate Professor Sir Martin Evans. Celixir is a British biotechnology company that discovers and develops life-saving and life-altering...
Stephen Deitch, Vice President,
C.R.A. Charles River Associates
Stephen Deitch is a vice president in the Life Sciences Practice at CRA. He has 30 years of experience in a variety of senior health care and life science positions as a consultant, payer, and pharmacist. Stephen has led engagements on a broad variety of commercial issues. He has worked across a...
Dr Josep Torrent-Farnell, Medicines Department,
Catalan Health Service
Dr. Josep Torrent-Farnell. PhD in Medicine and Surgery and Bachelor of Pharmacy, specialist in internal medicine and clinical pharmacology. Head of the medicine division of the CatSalut, of the Generalitat de Catalunya (May 2016). Full Professor of the Department of Clinical and Therapeutic...
Nigel Hughes, Scientific Director,
Janssen
Scientific Director, RMEDS Quantitative Sciences, Janssen Pharm R&D. A former UK NHS healthcare & voluntary sector professional working in the pharmaceutical and diagnostics industry with a 360° experience in the blood borne virus market based on a professional heritage in the viral...
Eva Marchese, Vice President,
C.R.A. Charles River Associates
Eva Marchese specializes in competitive strategy, pricing, market access, and research primarily in the pharmaceutical, biotech, and life sciences industries. She has an extensive consulting background with a focus on advising pharmaceutical and medical device companies on global pricing and market ...
Adam Heathfield, Senior Director of Global Health And Value Innovation Centre,
Pfizer Ltd
Adam has worked for Pfizer for 12 years. His current role is Senior Director in Pfizer’s Global Health and Value Innovation Center, working on new approaches to market access. Previously, Adam has worked in Pfizer’s international policy division and led Pfizer’s work on science policy in Europe...
Ajan Reginald, Chief Executive Officer,
Celixir
Ajan Reginald is a co-founder and the Chief Executive Officer of Celixir, which he originally founded under the name Cell Therapy Ltd in 2009 with Nobel Laureate Professor Sir Martin Evans. Celixir is a British biotechnology company that discovers and develops life-saving and life-altering...
Akshay Kumar, Senior Director,
Huron Consulting Group
Akshay Kumar – Senior Director -Dr. Akshay Kumar is a Senior Director with 11+ years of experience helping pharmaceutical and biotech companies develop market access & pricing solutions - which are aligned to their broader commercial, organizational and environmental context. These solutions...
Francois Lucas, Senior Director,
Huron Consulting Group
Francois Lucas - Senior Director -François has more than 20 of years of experience in consulting for the global healthcare industry, with expert knowledge of payer systems and pricing & market access strategy.François has worked across a broad array of therapy areas and geographies around the...
Vitaly Omelyanovskiy, General Director, Center Of Healthcare Quality Assessment And Control,
Federal State Budgetary Institution, the Center for Healthcare Quality Assessment and Control of the Ministry of Health of the Russian Federation
In 1987 he graduated from Pirogov Russian National Research Medical University with a specialization in “General Medicine”. In 1998 he graduated from the Russian Presidential Academy of National Economy and Public Administration with a specialization in “State and Municipal Management”. In 1991 he...
Ayman Semaan, Head of Market Access,
Algorithm
Ayman Semaan leads the Market Access Department at Algorithm/Biologix, covering 18 markets of the Middle East and North Africa (MENA); and holds a principal role in the group’s pricing committee.
His experience includes functional and leadership positions (Sales, Marketing, and Access) in various...
Wim Goettsch, Director of EUnetHTA JA3,
Zorginstituut
Wim Goettsch, PhD is the current Director of the EUnetHTA JA3 (2016-2020) Directorate. Between 2010 and 2015 he was the Project Leader of WP5 of the EUnetHTA JA1 and JA2 on Relative Effectiveness Assessments. Until the beginning of 2013, he was also the Deputy Secretary of the Medicinal Products...
Lotte Steuten, Associate Faculty Member,
Fred Hutchinson Cancer Research Center
Dr. Lotte Steuten is an entrepreneurial academic, striving to accelerate patient access to high-value healthcare innovations. She has deep expertise in health economics and evidence development that she applies to identifying and articulating the clinical, humanistic and economic value of medical...
Joerg Mahlich, Head Heor,
Janssen Pharmaceutical K.K.
Jörg Mahlich graduated in economics from the University of Kiel/Germany and holds a doctoral degree in economics from the University of Vienna/Austria. He is currently heading the health economics department at Janssen Japan in Tokyo. Previous to that he was in the market access team of Janssen...
Goedele Van Haasteren, Hta Specialist,
Bundesamt fur Gesundheit
Health Technology Assessment (HTA) specialist with profound experience in technology assessment, development of evidence-based practice guidelines and teaching materials, clinical research, consulting related to health technologies, and academic teaching.
Wim Goettsch, Director of EUnetHTA JA3,
Zorginstituut
Wim Goettsch, PhD is the current Director of the EUnetHTA JA3 (2016-2020) Directorate. Between 2010 and 2015 he was the Project Leader of WP5 of the EUnetHTA JA1 and JA2 on Relative Effectiveness Assessments. Until the beginning of 2013, he was also the Deputy Secretary of the Medicinal Products...
